中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

116 records (took 0.021 seconds)

    SPECIFIC DELIVERY OF DRUGS TO THE BRAIN
    33.
    发明专利
    SPECIFIC DELIVERY OF DRUGS TO THE BRAIN 未知

    公开(公告)号：CA2540695A1

    公开(公告)日：2004-12-29

    申请号：CA2540695

    申请日：2004-06-15

    Applicant: BAXTER INT

    Inventor： RABINOW BARRETT E ,  GENDELMAN HOWARD E ,  KIPP JAMES E

    IPC: A61K9/14 ,  A61K9/00 ,  A61K9/51 ,  A61K47/48

    Abstract: The present invention is concerned with delivering a pharmaceutical composition to the brain of a mammalian subject for treating brain diseases or disorders. The process includes the steps of: (i) providing a dispersion of the pharmaceutical composition as particles having an average particle size of from about 150 nm to about 100 microns, and (ii) administering the dispersion to the mammalian subject for delivery to the brain of a portion of the pharmaceutical composition by cells capable of reaching the brain. The dispersion of the pharmaceutical composition as particles, for example, can be phagocytized or adsorbed by the cells prior or subsequent to administration into the mammalian subject. The dispersion of the pharmaceutical composition can be administered to the central nervous system or the vascular system. After administration, the loaded cells transport the pharmaceutical composition as particles into the brain.

    35.
    发明专利
    未知

    公开(公告)号：BRPI0618653A2

    公开(公告)日：2011-09-06

    申请号：BRPI0618653

    申请日：2006-11-15

    Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

    Inventor： KIPP JAMES E ,  GUPTA PRAMOD

    IPC: A61K47/48 ,  A61K31/38 ,  A61P11/06 ,  A61P29/00 ,  A61P37/08

    Abstract: The present invention is directed to formulations of inclusion complexes of lipoxygenase inhibitors and cyclodextrins having a therapeutically effective concentration of the lipoxygenase inhibitor, methods of making the same and methods of treating disease states using the same. Forming cyclodextrin complexes permits the enhancement of the aqueous solubility of lipoxygenase inhibitors which allows higher concentrations of the lipoxygenase in solution. Aqueous formulations of lipoxygenase inhibitors-cyclodextrin complexes are suitable for parenteral or oral administration for treating and/or preventing inflammatory disease states. The aqueous formulations can be lyophilized to prolong storage stability, assist in oral administration and/or provide for convenient and economical packaging.

    Compositions of lipoxygenase inhibitors
    36.
    发明专利
    Compositions of lipoxygenase inhibitors 未知

    公开(公告)号：ZA200805000B

    公开(公告)日：2009-05-27

    申请号：ZA200805000

    申请日：2008-06-09

    Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

    Inventor： KIPP JAMES E ,  JANE WERLING ,  PRAMOD GUPTA ,  RITA BURESH

    IPC: A61K20090101 ,  A61P20090101

    Abstract: Pharmaceutical compositions comprising particles of lipoxygenase inhibitor compounds having an effective average size of from about 10 nm to about 50 microns are provided. More particularly, pharmaceutical compositions of particle of a 5-lipoxygenase inhibitor compound having an effective average size of from about 50 nm to about 5 microns are provided. The pharmaceutical compositions are in the form of aqueous suspensions with the particle of the 5-lipoxygenase inhibitor compound present in concentrations of from about 5 to about 200 mg/ml. In addition, methods for making such pharmaceutical compositions are provided. In particular, microprecipitation and direct homogenization in the presence of at least one surfactant are disclosed for making the pharmaceutical compositions.

    37.
    发明专利
    未知

    公开(公告)号：BRPI0510271A

    公开(公告)日：2007-10-30

    申请号：BRPI0510271

    申请日：2005-06-08

    Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

    Inventor： KIPP JAMES E ,  RABINOW BARRETT E

    IPC: C12N5/06 ,  A61K9/14 ,  A61K35/12 ,  A61K45/00 ,  A61K47/48 ,  A61K49/00

    Abstract: The present invention is concerned with a method of preparing and delivering small particles of a pharmaceutically active material to a mammalian subject for treating diseases or disorders. A preferred embodiment entails: (i) the collection of tissue cells from an animal donor, (ii) selective or non-selective growth of these cells in a cell culture medium to which is added solid particles of a therapeutically active compound, mostly free of a drug carrier (about 10% or less, by weight), and having an average particle size of less than about 100 microns, (iii) contacting the cells in the cell culture medium with the solid particles of therapeutically active compound causing the particles to be taken up by the cells into either the intracellular compartment of the cultured cells, attachment of the active compound as particles to the periphery of such cells, or a combination of intracellular uptake and attachment to the cell surface, (iv) optionally, isolation and/or resuspension of the cells prepared in steps i through iii, (v) administering the cells to the mammalian subject. The pharmaceutically active material can be administered intravenously, intramuscularly, subcutaneously, intradermally, intra-articularly, intrathecally, epidurally, intracerebrally, via buccal route, rectally, topically, transdermally, orally, intranasally, via pulmonary route, intraperitoneally, or combinations thereof. After administration, the loaded cells transport the pharmaceutical composition as particles.

Patent Agency Ranking